The life sciences industry is in a position to help humanity, perhaps more than ever, with the introduction of generative AI (GenAI). Lengthy drug development timelines and complex regulatory ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...